July 17, 2020 /
““““““““““““““
Jeffrey M. Kaplan, MD, and Matthew J. Baker, MD, discuss implications of treating patients with relapsing-remitting multiple sclerosis based on a recent study that evaluated time to first qualifying relapse in patients treated with cladribine in CLARITY study followed by placebo in CLARITY extension study.
::::::::::::::::::::::::::::::::::::::;;;;;;;;;;;;;;;;;;;;;::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Information Shared by: MSViewsandNews,
to and for those affected by Multiple Sclerosis
::::::::::::::::::::::::::::::::::::::;;;;;;;;;;;;;;;;;;;;;:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
